Skip to main content

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.

Publication ,  Journal Article
Isaacs, JD; Manna, VK; Rapson, N; Bulpitt, KJ; Hazleman, BL; Matteson, EL; St Clair, EW; Schnitzer, TJ; Johnston, JM
Published in: Br J Rheumatol
March 1996

Forty-one patients with active and refractory rheumatoid arthritis(RA) received a total of 100, 250 or 400 mg of CAMPATH-1H (CAMPATH is a trademark of Glaxo-Wellcome group companies, registered in the US Patent and Trademark Office) over 5 or 10 days in an open, uncontrolled study. Following therapy, patients were monitored for adverse effects and disease activity for 6 months. Therapy was associated with prolonged peripheral blood lymphopenia in all dosing cohorts. During the month immediately following therapy, lymphopenia was most profound in the 400 mg cohorts. The first dose of monoclonal antibody (Mab) was associated with a 'flu'-like syndrome, more pronounced at higher initial doses. One patient developed haemolytic-uraemic syndrome. There were a number of dose-related infections during the early post-treatment period and one fatal opportunistic infection which followed additional immunosuppressive therapy. Antiglobulin responses developed in 9 of 31 patients tested. The majority of patients showed symptomatic improvement following therapy and 20% of patients maintained a 50% Paulus response at 6 months, all of whom were in the 250 or 400 mg cohorts. CAMPATH-1H appears to be an effective treatment for RA. Allowing for the small number of patients treated, infections were more common with higher doses, although this was not true for adverse events overall, and therapeutic responses were more sustained at higher dosing levels. The broad specificity of CAMPATH-1H may be appropriate for the immunotherapy of RA and future studies should aim to define a dose with an optimal therapeutic ratio.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Br J Rheumatol

DOI

ISSN

0263-7103

Publication Date

March 1996

Volume

35

Issue

3

Start / End Page

231 / 240

Location

England

Related Subject Headings

  • Time Factors
  • Pain Measurement
  • Middle Aged
  • Male
  • Lymphocyte Count
  • Joints
  • Injections, Intravenous
  • Humans
  • Female
  • Dose-Response Relationship, Immunologic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Isaacs, J. D., Manna, V. K., Rapson, N., Bulpitt, K. J., Hazleman, B. L., Matteson, E. L., … Johnston, J. M. (1996). CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol, 35(3), 231–240. https://doi.org/10.1093/rheumatology/35.3.231
Isaacs, J. D., V. K. Manna, N. Rapson, K. J. Bulpitt, B. L. Hazleman, E. L. Matteson, E. W. St Clair, T. J. Schnitzer, and J. M. Johnston. “CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.Br J Rheumatol 35, no. 3 (March 1996): 231–40. https://doi.org/10.1093/rheumatology/35.3.231.
Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, et al. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol. 1996 Mar;35(3):231–40.
Isaacs, J. D., et al. “CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.Br J Rheumatol, vol. 35, no. 3, Mar. 1996, pp. 231–40. Pubmed, doi:10.1093/rheumatology/35.3.231.
Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St Clair EW, Schnitzer TJ, Johnston JM. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol. 1996 Mar;35(3):231–240.

Published In

Br J Rheumatol

DOI

ISSN

0263-7103

Publication Date

March 1996

Volume

35

Issue

3

Start / End Page

231 / 240

Location

England

Related Subject Headings

  • Time Factors
  • Pain Measurement
  • Middle Aged
  • Male
  • Lymphocyte Count
  • Joints
  • Injections, Intravenous
  • Humans
  • Female
  • Dose-Response Relationship, Immunologic